• Aleafia Health Inc. (AH) has appointed two new independent directors
  • The company hired Lu Galasso and Carlo Sistilli to its Board
  • Galasso will be appointed to the strategic planning committee
  • Sistilli will be appointed to the audit committee
  • Aleafia Health Inc. is up 1.41 per cent to C$0.72 per share

Aleafia Health Inc. (AH) has appointed two new independent directors.

The company hired Lu Galasso and Carlo Sistilli to its Board.

Galasso will be appointed to the strategic planning committee and Sistilli will be appointed to the audit committee.

“I would like to welcome Lu and Carlo to our Board,” said acting chair Lea Ray.

“Their collective professional experience will bring unique skills to the board that will serve Aleafia Health well in its continued growth.”

Galasso is a Chartered Professional Accountant, CA, CPA and holds the Institute of Corporate Directors ICD.D designation.

He is also a partner with the Zzen Group of Companies, a company in the real estate and manufacturing sectors, where he is the CFO and head of strategic developments for the manufacturing operations.

Sistilli is a Chartered Professional Accountant and a Certified Management Accountant, CPA, CMA. As Chief Financial Officer and member of the Senior Management team of Arista Homes, Sistilli played a key role in overall operations including evaluation of mergers and acquisitions.

Prior to Arista, Sistilli co-founded and served as CFO, member of the M&A team and member of the Board of Directors of an Internet start-up company, helping to take the company public on the Alberta Ventures Exchange.

Aleafia Health is a vertically integrated and federally licensed Canadian cannabis company offering cannabis health and wellness services and products in Canada and in international markets.

Aleafia Health Inc. is up 1.41 per cent to C$0.72 per share.

More From The Market Online

Tilray Brands seeks US$250M for U.S. cannabis expansion

Global cannabis stock Tilray Brands (TSX:TLRY) intends to raise up to US$250 million to fund its U.S. expansion plan.

The Market Online’s Weekly Cannabis Report – May 17, 2024

This international biopharmaceutical company revealed it has completed the retrospective observational real-world evidence study.

Avicanna finishes study of CBD cream’s use for rare skin disorder

Avicanna (TSX:AVCN) completes an observational study of its RHO Phyto-branded Ultra CBD topical cream on patients with epidermolysis bullosa.